Korean pharmaceutical company Hanmi Pharmaceutical Co., Ltd. popped up on the healthcare M&A radar last week with two collaboration announcements. First was an agreement with French drug maker Sanofi (NYSE: SNY) to grant the worldwide license to a yet-to-be developed portfolio of experimental, long-acting diabetes treatments. Sanofi paid an upfront fee of €400 million ($434,820,000) and is eligible for up to €3.5 billion in development, registration and sales milestone, as well as double digit royalties on net sales. The second deal, with Janssen Pharmacticals, Inc. (NYSE: JNJ), was for the rights to oxyntomodulin-based therapies, including Hanmi’s NM12525A. Janssen paid $105 million upfront, and could pay up to $810 million in potential clinical, regulatory and sales milestones. If the drug is successful, Hanmi would also be eligible for tiered double-digit royalty payments.